Relation of the profile of eff ectiveness and safety of bromodihydro chlorophenylbenzodiazepine with the CYP2C19*2 polymorphism in patients with...
Застрожин М., Гришина Е., Скрябин В., Галактионова Т., Барна И., Вдовина М., Матcкевич В., Пахомов С., Савченко Л., Брун Е., Сычев Д. А., Юрова М. В.
Психиатрия, психотерапия и клиническая психология
Т. 9, Вып. 2, С. 246-260
Опубликовано: 2018
Тип ресурса: Статья
Аннотация:
Bromodihydrochlorophenylbenzodiazepine (phenazepam) is used in the therapy of anxiety disorders in patients with alcohol dependence. However, phenazepam therapy often turns out to be ineff ective, and some patients develop dose-related adverse drug reactions (ADR): severe sedation, dizziness, headache, dyspepsia, falling, etc. It reduces the eff ectiveness of treatment of this category of patients. Despite the popularity of phenazepam as anxiolytic drug, there is currently no accurate data on its biotransformation, as well as the eff ect of polymorphism of the gene on the eff ectiveness and safety of bromodihydrochlorophenylbenzodiazepine. The aim of our research was to study the eff ect of polymorphism of the CYP2C19 gene on the eff ectiveness and safety index of phenazepam in patients with anxiety disorders, using the algorithms for optimization of therapy with phenazepam® to reduce the risk of pharmacological resistance and development of dose-dependent NRL. The study included 86 Ru
Ключевые слова:
Benzodiazepines; Biotransformation; Bromodihydrochlorobenzodiazepine; CYP2C19; Personalized medicine; Pharmacogenetics; Phenazepame
Язык текста: Русский
ISSN: 2414-2212
Застрожин М.
Гришина Е.
Скрябин В.
Галактионова Т.
Барна И.
Вдовина М.
Матcкевич В.
Пахомов С.
Савченко Л.
Брун Е.
Сычев Д. А. Дмитрий Алексеевич 1975-
Юрова М. В. Мария Владимировна 1993-
Zastrozhin M.
Grishina E.
Skryabin V.
Galaktionova T.
Barna I.
Vdovina M.
Matckevich V.
Pakhomov S.
Savchenko L.
Brun E.
Sy'chev D. A. Dmitrij Alekseevich 1975-
Yurova M. V. Mariya Vladimirovna 1993-
Relation of the profile of eff ectiveness and safety of bromodihydro chlorophenylbenzodiazepine with the CYP2C19*2 polymorphism in patients with anxiety disorders and comorbid alcohol addiction
Relation of the profile of eff ectiveness and safety of bromodihydro chlorophenylbenzodiazepine with the CYP2C19*2 polymorphism in patients with...
Текст визуальный непосредственный
Психиатрия, психотерапия и клиническая психология
Т. 9, Вып. 2 С. 246-260
2018
Статья
Benzodiazepines Biotransformation Bromodihydrochlorobenzodiazepine CYP2C19 Personalized medicine Pharmacogenetics Phenazepame
Bromodihydrochlorophenylbenzodiazepine (phenazepam) is used in the therapy of anxiety disorders in patients with alcohol dependence. However, phenazepam therapy often turns out to be ineff ective, and some patients develop dose-related adverse drug reactions (ADR): severe sedation, dizziness, headache, dyspepsia, falling, etc. It reduces the eff ectiveness of treatment of this category of patients. Despite the popularity of phenazepam as anxiolytic drug, there is currently no accurate data on its biotransformation, as well as the eff ect of polymorphism of the gene on the eff ectiveness and safety of bromodihydrochlorophenylbenzodiazepine. The aim of our research was to study the eff ect of polymorphism of the CYP2C19 gene on the eff ectiveness and safety index of phenazepam in patients with anxiety disorders, using the algorithms for optimization of therapy with phenazepam® to reduce the risk of pharmacological resistance and development of dose-dependent NRL. The study included 86 Ru